Literature DB >> 1390487

PhXA34--a prostaglandin F2 alpha analogue. Effect on intraocular pressure in patients with ocular hypertension.

J Villumsen1, A Alm.   

Abstract

PhXA34, a prostaglandin analogue, was given topically to 40 patients with untreated ocular hypertension in a double masked randomised study. One single dose of 0.3, 1, 3, 10 micrograms, or placebo (vehicle) was given to one eye of each patient. A dose related IOP reduction ranging from 11 to 35% was observed with a maximal effect with 3 and 10 micrograms PhXA34. No hyperaemia was seen except after 10 micrograms PhXA34, where a mild to moderate hyperaemia was seen from 8 hours with a duration of up to 24 hours. Mild foreign body sensation in the PhXA34-treated eye was noted by three patients. No cells or flare were seen.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1390487      PMCID: PMC504230          DOI: 10.1136/bjo.76.4.214

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  4 in total

1.  Prostaglandin F2 alpha-isopropylester eye drops: effect on intraocular pressure in open-angle glaucoma.

Authors:  J Villumsen; A Alm; M Söderström
Journal:  Br J Ophthalmol       Date:  1989-12       Impact factor: 4.638

2.  Prostaglandin F2 alpha-isopropylester eye drops: effects in normal human eyes.

Authors:  J Villumsen; A Alm
Journal:  Br J Ophthalmol       Date:  1989-06       Impact factor: 4.638

3.  The effect of adding prostaglandin F2 alpha-isopropylester to timolol in patients with open angle glaucoma.

Authors:  J Villumsen; A Alm
Journal:  Arch Ophthalmol       Date:  1990-08

4.  PhXA34, a new potent ocular hypotensive drug. A study on dose-response relationship and on aqueous humor dynamics in healthy volunteers.

Authors:  A Alm; J Villumsen
Journal:  Arch Ophthalmol       Date:  1991-11
  4 in total
  11 in total

1.  Additive effect of latanoprost and dorzolamide in patients with elevated intraocular pressure.

Authors:  M Kimal Arici; A Topalkara; C Güler
Journal:  Int Ophthalmol       Date:  1998       Impact factor: 2.031

2.  The effect of latanoprost 0.005% once daily versus 0.0015% twice daily on intraocular pressure and aqueous humour protein concentration in glaucoma patients. A randomized, double-masked comparison with timolol 0.5%.

Authors:  M Diestelhorst; S Roters; G K Krieglstein
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1997-01       Impact factor: 3.117

Review 3.  Latanoprost. A review of its pharmacological properties, clinical efficacy and tolerability in the management of primary open-angle glaucoma and ocular hypertension.

Authors:  S S Patel; C M Spencer
Journal:  Drugs Aging       Date:  1996-11       Impact factor: 3.923

4.  A double masked comparison of the intraocular pressure reducing effect of latanoprost 0.005% and 0.001% administered once daily in open angle glaucoma and ocular hypertension.

Authors:  B Friström; S E Nilsson
Journal:  Br J Ophthalmol       Date:  1997-10       Impact factor: 4.638

5.  The impact of intraocular pressure reduction on retinal ganglion cell function measured using pattern electroretinogram in eyes receiving latanoprost 0.005% versus placebo.

Authors:  Mitra Sehi; Dilraj S Grewal; William J Feuer; David S Greenfield
Journal:  Vision Res       Date:  2010-09-08       Impact factor: 1.886

6.  Latanoprost--a promising new glaucoma drug.

Authors:  S Nagasubramanian
Journal:  Br J Ophthalmol       Date:  1995-01       Impact factor: 4.638

7.  The effect of latanoprost on aqueous humor PGF2alpha levels in glaucoma patients.

Authors:  D Güven; A Karakurt; E Saban; H Hasiripi
Journal:  Int Ophthalmol       Date:  1999       Impact factor: 2.031

Review 8.  Prostaglandin analogues in the treatment of glaucoma.

Authors:  C Lindén; A Alm
Journal:  Drugs Aging       Date:  1999-05       Impact factor: 3.923

9.  Additive effect of latanoprost, a prostaglandin F2 alpha analogue, and timolol in patients with elevated intraocular pressure.

Authors:  A H Rulo; E L Greve; P F Hoyng
Journal:  Br J Ophthalmol       Date:  1994-12       Impact factor: 4.638

10.  Animal model for uveitic glaucoma.

Authors:  A Mermoud; G Baerveldt; D S Mickler; G S Wu; N A Rao
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1994-09       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.